N6022 clinical trials
Also written N6022.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses N6022 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- N6022
- 3
Studies by the year they started
3 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses N6022 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR MutationCompletedPhase 1Nivalis Therapeutics, Inc.NCT01746784Written as N6022
- Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild AsthmaCompletedPhase 1/2Nivalis Therapeutics, Inc.NCT01316315Written as Active
- Safety and Tolerability Study of N6022 in Healthy SubjectsCompletedPhase 1Nivalis Therapeutics, Inc.NCT01147406Written as N6022